Study of Epratuzumab (hLL2) in Patients With Waldenstrom's Macroglobulinemia

Stopped early · Phase 2

Conditions studied: Waldenstrom Macroglobulinemia

In brief

The purpose of this study is to determine whether epratuzumab provides effective therapy in Waldenström's Macroglobulinemia (WM).

Key facts

Study ID

NCT00113802

Run by

Gilead Sciences

People needed

31

Starts

2004-08-01

Expected to finish

2006-12-01

Last updated by the study team

2021-08-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Documented diagnosis of Waldenström's Macroglobulinemia using criteria proposed at 2nd International Workshop on WM, Athens, Greece, 2002.
• Measurable disease, defined as serum monoclonal IgM protein ≥1000 mg/dL by electrophoresis.
• Lymphoplasmacytic infiltration of the bone marrow >10% involvement.
• Failed at least one, but no more than 3, regimen(s) of prior therapy.
• (Please consult with study site for full eligibility criteria)

Where it is running

• Weill Medical College of Cornell/ New York Presbyterian Hospital — New York, New York, United States
• Columbia University College of Physicans & Surgeons — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.